021-51111890
购物车（）
sales@molnova.cn
Cinepazide maleate
CAS No. 26328-04-1
Cinepazide maleate ( —— )
产品货号. M13807 CAS No. 26328-04-1
作为钙阻滞剂的脑血管扩张剂；通过抑制 OGD 诱导的氧化应激和保护线粒体功能，保护神经元细胞免受 OGD 损伤。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | ￥405 | 有现货 |
|
| 50MG | ￥527 | 有现货 |
|
| 100MG | ￥907 | 有现货 |
|
| 200MG | ￥1604 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cinepazide maleate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述作为钙阻滞剂的脑血管扩张剂；通过抑制 OGD 诱导的氧化应激和保护线粒体功能，保护神经元细胞免受 OGD 损伤。
-
产品描述A cerebral vasodilator that acts as a calcium blocker; protect neuronal cells against OGD injury by suppressing OGD-induced oxidative stress and preserving mitochondrial functions.Ischemia Approved(In Vitro):Cinepazide Maleate (intravenous injection; 30 mg/kg) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP, while cinnarizine reduces their vasodilator effects.Cinepazide Maleate (intravertebral injection; 1-10 mg/kg) increases vertebral blood flow in a dose-related manner in dogs.
-
体外实验——
-
体内实验Cinepazide Maleate (intravenous?injection; 30 mg/kg) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP, while cinnarizine reduces their vasodilator effects.Cinepazide Maleate (intravertebral injection; 1-10 mg/kg) increases vertebral blood flow in a dose-related manner?in dogs.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域Cardiovascular Disease
-
适应症Ischemia
化学信息
-
CAS Number26328-04-1
-
分子量533.5708
-
分子式C26H35N3O9
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCOC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3.C(=C\C(=O)O)\C(=O)O
-
化学全称Piperazine, 1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-, (E)-, (2Z)-2-butenedioate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Miwa S, et al. Jpn J Pharmacol. 1986 May;41(1):109-15.
2. Zhao J, et al. Neurol Sci. 2014 Jun;35(6):875-81.
3. Li Y, et al. Biol Pharm Bull. 2017 Mar 1;40(3):249-255.
